drugset / Trial / NCT02870244
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NaSingle-groupOpen-labelTreatment
Summary
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
Timeline
- Start
- 2015-02
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 7.5e+06 cells/kg | — |
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 2.5e+07 cells/kg | — |
| Subject | TIL 1383I TCR transduced T cells | Cell therapy | 7.5e+07 cells/kg | — |
| Background | IL-2 | Protein / enzyme biologic | — | — |